ABO Ç÷¾×Çü ºÎÀûÇÕ ½ÅÀåÀÌ½Ä È¯ÀÚ¿¡¼ Ç÷¿¬ °£ ½ÅÀåÀ̽İú ºñÇ÷¿¬ °£ ½ÅÀåÀ̽ÄÀÇ ¼ºÀû ºñ±³
Clinical Outcomes between Living Related and Living Unrelated Kidney Transplantation in ABO-Incompatible Kidney Transplant Recipients
´ëÇѳ»°úÇÐȸÁö 2014³â 87±Ç 6È£ p.698 ~ p.704
¹Ú¿ì¿µ(Park Woo-Young) - °è¸í´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Çѽ¿±(Han Seung-Yeup) - °è¸í´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
ȲÀº¾Æ(Hwang Eun-Ah) - °è¸í´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¹Ú¼º¹è(Park Sung-Bae) - °è¸í´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¹ÚÀÇÁØ(Park Ui-Jun) - °è¸í´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
±èÇüÅÂ(Kim Hyoung-Tae) - °è¸í´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
Á¶¿øÇö(Cho Won-Hyun) - °è¸í´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
Abstract
¸ñÀû: ½ÅÀåÀ̽ÄÀº ¸»±â ½ÅºÎÀü ȯÀÚÀÇ Ä¡·á¿¡ ÀÖ¾î °¡Àå È¿°úÀûÀÎ ½Å´ëü ¿ä¹ýÀÌ´Ù. °ú°Å ABO Ç÷¾×Çü ÀûÇÕ ½ÅÀåÀ̽Ŀ¡¼ Ç÷¿¬ °ø¿©ÀÚ ½ÅÀåÀ̽ÄÀÌ ºñÇ÷¿¬ °ø¿©ÀÚ ½ÅÀåÀ̽ĺ¸´Ù ¼ºÀûÀÌ ÁÁ´Ù°í º¸°í µÇ¾úÀ¸³ª ÃÖ±Ù¿¡´Â ¼ºÀû¿¡ Â÷ÀÌ°¡ ¾ø´Ù°í º¸°íµÇ°í ÀÖ´Ù. ABO Ç÷¾×Çü ºÎÀûÇÕ ½ÅÀåÀ̽Ŀ¡¼ Ç÷¿¬ °£ ½ÅÀåÀ̽İú ºñÇ÷¿¬ °£ ½ÅÀåÀÌ½Ä ¼ºÀûÀ» ºñ±³ÇÏ¿´´Ù.
¹æ¹ý: 2011³â 1¿ùºÎÅÍ 2013³â 8¿ù±îÁö ABO Ç÷¾×Çü ºÎÀûÇÕ ½ÅÀåÀÌ½Ä 19¿¹°¡ ÈÄÇâÀûÀ¸·Î ºÐ¼®µÇ¾ú´Ù. Ç÷¿¬ °£ ½ÅÀåÀ̽ÄÀº 8¿¹(ºÎ¸ð-ÀÚ½Ä °£ 7¿¹, ÇüÁ¦°£ 1¿¹), ºñÇ÷¿¬ °£ ½ÅÀåÀ̽ÄÀº 11¿¹(¹è¿ìÀÚ °£ 11¿¹)¿´´Ù. ABO Ç÷¾×Çü ºÎÀûÇÕ ½ÅÀåÀ̽Ŀ¡¼ Ç÷¿¬ °£ ½ÅÀåÀ̽ıº°ú ºñÇ÷¿¬ °£ ½ÅÀåÀ̽ıºÀÇ È¯ÀÚ ¹× ÀÌ½Ä ½ÅÀå »ýÁ¸À², ±Þ¼º °ÅºÎ¹ÝÀÀ, ÀÌ½Ä ½ÅÀå ±â´É, ÇÕº´Áõ¿¡ ´ëÇØ Á¶»çÇÏ¿´´Ù.
°á°ú: Kaplan-Meier ºÐ¼®¿¡ µû¶ó Ç÷¿¬ °£ ½ÅÀåÀ̽ıº¿¡¼ ÃßÀû ±â°£ µ¿¾È ȯÀÚ »ýÁ¸À² ¹× ÀÌ½Ä ½ÅÀå »ýÁ¸À²Àº °¢°¢ 87.5%, 87.5%¿´°í ºñÇ÷¿¬ °£ ½ÅÀåÀ̽ıº¿¡¼ ¸ðµÎ 100%¿´´Ù. ±Þ¼º °ÅºÎ¹ÝÀÀ, ÀÌ½Ä ½ÅÀå ±â´É, ³»¿Ü°úÀû ÇÕº´ÁõÀº ¾ç±º°£¿¡ ÀÇ¹Ì ÀÖ´Â Â÷ÀÌ°¡ ¾ø¾ú´Ù.
°á·Ð: ABO Ç÷¾×Çü ºÎÀûÇÕ ½ÅÀåÀ̽Ŀ¡¼ Ç÷¿¬ °£ ½ÅÀåÀ̽İú ºñÇ÷¿¬ °£ ½ÅÀåÀÌ½Ä ´Ü±â ¼ºÀûÀÇ Â÷ÀÌ°¡ ¾ø¾ú´Ù. ±¹³» ºñÇ÷¿¬ °£ ½ÅÀåÀ̽ÄÀÇ ´ëºÎºÐÀº ¹è¿ìÀÚ °£ ½ÅÀåÀ̽ÄÀ¸·Î ¹è¿ìÀÚ´Â ABO Ç÷¾×Çü ºÎÀûÇÕ ½ÅÀåÀ̽ÄÀÇ ÁÖ¿ä °ø¿©ÀÚ°¡ µÉ ¼ö ÀÖÀ» °ÍÀÌ´Ù.
Background/Aims: Kidney transplantation (KT) is the best treatment for end-stage renal disease patients. Although previous studies have demonstrated that the clinical outcome following living related (LR) KT is better than that following unrelated (LUR) KT in ABO-compatible KT recipients, recent studies showed no differences in clinical outcomes between the two treatments. In this study, we compared the clinical outcomes of LR and LUR KT in ABO-incompatible KT recipients.
Methods: From January 2011 to August 2013, 19 cases of ABO-incompatible KT were analyzed retrospectively. Eight kidneys (7 cases of parent-offspring and 1 case of siblings, Group 1) were donated from living-related donors and 11 (all spousal donors, Group 2) from living-unrelated donors. We investigated patient survival, graft survival, acute rejection, graft function, and complications.
Results: On Kaplan-Meier analysis, patient and graft survival during follow-up were 87.5% and 87.5% in Group 1; both were 100% in Group 2. Acute rejection, graft function, and medical and surgical complications were not significantly different between the two groups.
Conclusions: The short-term clinical outcomes between LR and LUR KT in ABO-incompatible KT recipients were equivalent. Most domestic cases of LUR KT are from spousal donors and the spousal donor will be a major donor in ABO-incompatible KT patients.
Å°¿öµå
½ÅÀåÀ̽Ä, ºñÇ÷¿¬°ø¿©ÀÚ, ABO Ç÷¾×Çü ºÎÀûÇÕ
Kidney transplantation, Living-unrelated, ABO-incompatible
KMID :
0882420140870060698
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)